[Adverse events from the Pfizer-BioNTech® COVID-19vaccine in children 5-17 years old].

María Del Rocío Hernández Morales, Margarita Aguirre Barbosa, Eleazar Mancilla Hernández, Sandra Aidée González Hidalgo, Estefanía Alavez López, Sandra Maldonado Castañeda
{"title":"[Adverse events from the Pfizer-BioNTech® COVID-19vaccine in children 5-17 years old].","authors":"María Del Rocío Hernández Morales, Margarita Aguirre Barbosa, Eleazar Mancilla Hernández, Sandra Aidée González Hidalgo, Estefanía Alavez López, Sandra Maldonado Castañeda","doi":"10.29262/ram.v71i3.1387","DOIUrl":null,"url":null,"abstract":"<p><strong>Objetives: </strong>To describe the events supposedly attributable to immunization with the Pfizer-BioNTech® COVID-19 vaccine in children aged 5 to 17 years in the state of Puebla, Mexico.</p><p><strong>Methods: </strong>Observational, cross-sectional and descriptive study carried out based on the analysis of reports of events supposedly attributable to immunization in children aged 5 to 17 years, who received the vaccine with the BNT162b2 mRNA platform for COVID-19, since January. to December 2022. Percentages, frequencies, averages, standard deviations and medians were used for statistical analysis. The Statistical Package for the Social Sciences 23 program was implemented.</p><p><strong>Results: </strong>1,993,373 doses of the BNT162b2 vaccine were administered. 52 events presumed to be attributable to vaccination or immunization were reported. An annual rate of 2.6 per 100,000 doses applied was estimated. The age distribution recorded a median of 10.50 years (SD: 3.53). There were 56% women and 44% men; The most frequent symptoms were: dizziness, nausea, vomiting and pain at the vaccine application site. 2 cases of seizures and 1 of flaccid paralysis were reported.</p><p><strong>Conclusions: </strong>The safety of vaccines against SARS-CoV-2 requires an improvement in strategies for epidemiological surveillance (passive and active), with a more robust approach to guarantee safe vaccination.</p>","PeriodicalId":101421,"journal":{"name":"Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)","volume":"71 3","pages":"139-145"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29262/ram.v71i3.1387","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objetives: To describe the events supposedly attributable to immunization with the Pfizer-BioNTech® COVID-19 vaccine in children aged 5 to 17 years in the state of Puebla, Mexico.

Methods: Observational, cross-sectional and descriptive study carried out based on the analysis of reports of events supposedly attributable to immunization in children aged 5 to 17 years, who received the vaccine with the BNT162b2 mRNA platform for COVID-19, since January. to December 2022. Percentages, frequencies, averages, standard deviations and medians were used for statistical analysis. The Statistical Package for the Social Sciences 23 program was implemented.

Results: 1,993,373 doses of the BNT162b2 vaccine were administered. 52 events presumed to be attributable to vaccination or immunization were reported. An annual rate of 2.6 per 100,000 doses applied was estimated. The age distribution recorded a median of 10.50 years (SD: 3.53). There were 56% women and 44% men; The most frequent symptoms were: dizziness, nausea, vomiting and pain at the vaccine application site. 2 cases of seizures and 1 of flaccid paralysis were reported.

Conclusions: The safety of vaccines against SARS-CoV-2 requires an improvement in strategies for epidemiological surveillance (passive and active), with a more robust approach to guarantee safe vaccination.

[5-17岁儿童服用辉瑞- biontech®covid -19疫苗的不良事件]。
目的:描述墨西哥普埃布拉州5至17岁儿童接种辉瑞- biontech®COVID-19疫苗可能导致的事件。方法:对1月以来接种新型冠状病毒BNT162b2 mRNA平台疫苗的5 ~ 17岁儿童的免疫事件报告进行观察性、横断面和描述性研究。到2022年12月。采用百分比、频率、平均值、标准差和中位数进行统计分析。实施了“社会科学统计一揽子计划”。结果:共接种了1,993,373剂BNT162b2疫苗。报告了52起推定可归因于疫苗接种或免疫接种的事件。据估计,每100 000剂中每年有2.6人死亡。年龄分布中位数为10.50岁(SD: 3.53)。其中女性占56%,男性占44%;最常见的症状是:眩晕、恶心、呕吐和接种部位疼痛。报告癫痫发作2例,弛缓性麻痹1例。结论:SARS-CoV-2疫苗的安全性需要改进流行病学监测策略(被动和主动),并采取更有力的方法来保证疫苗接种的安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信